Related Experiment Video

Updated: Aug 8, 2026

Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice
10:31

Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice

Published on: May 2, 2025

Glucose-Independent Metabolic Signatures of SGLT2 Inhibition in Diabetic Kidney Disease: Integrated Insights from

Yang Zhou1, Jie Peng2,3, Xuchang Zhou4

  • 1Department of Epidemiology and Biostatistics, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences; School of Basic Medicine, Peking Union Medical College, Beijing, China.

Diabetes & Metabolism Journal
|August 7, 2026
PubMed
Abstract

Insights

Sodium-glucose co-transporter 2 (SGLT2) inhibitors protect kidneys through glucose-independent metabolic changes. This study reveals how SGLT2 inhibition reprograms metabolism and reduces fibrosis, offering new therapeutic targets for diabetic kidney disease (DKD).

Area of Science:

  • Nephrology
  • Metabolomics
  • Genetics

Background:

  • Diabetic kidney disease (DKD) is a leading cause of kidney failure, with residual risk persisting despite glucose control.
  • Sodium-glucose co-transporter 2 (SGLT2) inhibitors offer kidney protection beyond glucose lowering, but non-glycemic mechanisms remain unclear.
  • Understanding these pathways is crucial for developing new therapies and optimizing DKD management.

Purpose of the Study:

  • To identify glucose-independent metabolic pathways involved in the renoprotective effects of SGLT2 inhibitors.
  • To uncover conserved molecular mechanisms underlying SGLT2 inhibition's benefits in kidney disease.

Main Methods:

  • A multi-omics framework integrating Mendelian randomization (MR) with transcriptomics was employed.
  • Two-sample and multivariable MR (MVMR) analyzed large-scale GWAS data to find glucose-independent metabolites.
  • Findings were validated using transcriptomic data from mouse kidney models.

Main Results:

  • Genetically proxied SGLT2 inhibition reduced DKD risk (OR 0.58) and improved renal function.
  • MVMR identified 259 glucose-independent metabolites linked to lipid and amino acid metabolism.
  • Seven key genes involved in fatty acid oxidation and ketone body utilization were identified, suggesting a metabolic switch and reduced fibrosis.

Conclusions:

  • SGLT2 inhibition promotes renoprotection via metabolic reprogramming and anti-fibrotic effects independent of glucose lowering.
  • This study provides genetic evidence for specific non-glycemic targets in DKD.
  • Findings offer novel mechanistic insights for precision therapeutic interventions in kidney disease.
Keywords:
Diabetic nephropathiesMendelian randomization analysisMetabolomicsSodium-glucose transporter 2 inhibitorsTranscriptome

Related Concept Videos

Glucose Transporters01:27

Glucose Transporters

Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Diabetic Nephropathy01:28

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Glucose Absorption Into the Small Intestine01:26

Glucose Absorption Into the Small Intestine

Complex carbohydrates consumed cannot be absorbed into the small intestine in their original form. First, they must be hydrolyzed to a monosaccharide form such as glucose or galactose. These monosaccharides are then transported across the intestinal membrane and into the blood via transcellular transport. The intestinal epithelial cells allow the movement of these monosaccharides with a defined 'entry' through membrane transporter proteins present on their apical membrane and 'exit' via the...